Selected Current Data on Metronomic Therapy (and Its Promise) from India

Overview

Journal South Asian J Cancer

Specialty Oncology

Date 2016 Jun 9

PMID 27275444

Citations 7

Authors

P M Parikh

S S Hingmire

C D Deshmukh

Affiliations

Soon will be listed here.

Citing Articles

Epidemiology, Diagnostics, and Therapy of Oral Cancer-Update Review.

Kijowska J, Grzegorczyk J, Gliwa K, Jedras A, Sitarz M Cancers (Basel). 2024; 16(18).

PMID: 39335128 PMC: 11430737. DOI: 10.3390/cancers16183156.

Oral Metronomic Chemotherapy in Advanced and Metastatic Oral Squamous Cell Carcinoma: A Need of the Hour.

Kumar N, Dikhit P, Jose A, Mehta V, Pai A, Kudva A J Maxillofac Oral Surg. 2024; 23(4):793-800.

PMID: 39118899 PMC: 11303669. DOI: 10.1007/s12663-023-01963-y.

Prostaglandin-endoperoxide synthase 2 (PTGS2) gene expression and its association with genes regulating the VEGF signaling pathway in head and neck squamous cell carcinoma.

Kamal M, Damerla R, Dikhit P, Kumar N J Oral Biol Craniofac Res. 2023; 13(5):567-574.

PMID: 37559688 PMC: 10407435. DOI: 10.1016/j.jobcr.2023.07.002.

A single-arm feasibility phase II study of EMF (erlotinib + methotrexate + 5-fluorouracil) regimen in platinum-refractory recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Baa A, Sharma A, Bhaskar S, Biswas A, JeeBharti S, Thakar A Ecancermedicalscience. 2022; 16:1451.

PMID: 36405947 PMC: 9666288. DOI: 10.3332/ecancer.2022.1451.

Dynamic changes in practical inflammation and immunity markers in cancer patients receiving immune-enhancing nutritional supplementation during concurrent chemoradiotherapy.

Homkham N, Muangwong P, Pisprasert V, Traisathit P, Jiratrachu R, Chottaweesak P Cancer Biomark. 2021; 32(3):281-291.

PMID: 34151843 PMC: 8673492. DOI: 10.3233/CBM-210086.

References

Pai P, Vaidya A, Prabhash K, Banavali S . Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous cell cancers: A matched-pair analysis. Indian J Cancer. 2013; 50(2):135-41. DOI: 10.4103/0019-509X.117024. View

Malik P, Raina V, Andre N . Metronomics as maintenance treatment in oncology: time for chemo-switch. Front Oncol. 2014; 4:76. PMC: 3989712. DOI: 10.3389/fonc.2014.00076. View

Parikh P, Prabhash K, Bhattacharyya G, Sirohi B, Rajappa S, Verma A . Ignore molecular oncology at your peril. Indian J Cancer. 2014; 51(2):150-3. DOI: 10.4103/0019-509X.138258. View

Patil V, Noronha V, Krishna V, Joshi A, Prabhash K . Oral metronomic chemotherapy in recurrent, metastatic and locally advanced head and neck cancers. Clin Oncol (R Coll Radiol). 2013; 25(6):388. DOI: 10.1016/j.clon.2013.01.002. View

Noronha V, Joshi A, Marfatia S, Patil V, Juvekar S, Arya S . Health-related quality of life in patients with metastatic, relapsed, or inoperable squamous cell carcinoma of the head and neck in India. Support Care Cancer. 2015; 24(4):1595-602. DOI: 10.1007/s00520-015-2937-9. View

Patil V, Noronha V, Joshi A, Muddu V, Dhumal S, Bhosale B . A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck. Oral Oncol. 2015; 51(3):279-86. DOI: 10.1016/j.oraloncology.2014.12.002. View

Andre N, Pasquier E . Metronomics in low and middle income countries: India showing the way!. Indian J Cancer. 2013; 50(2):112-4. DOI: 10.4103/0019-509X.117026. View

Bahl A, Bakhshi S . Metronomic chemotherapy in progressive pediatric malignancies: old drugs in new package. Indian J Pediatr. 2012; 79(12):1617-22. DOI: 10.1007/s12098-012-0759-z. View

Sondhi V, Kurkure P, Jalali R, Rangarajan V, Sridhar E, Medhi S . Complete remission and long-term survival in a child with relapsed medulloblastoma with extensive osteosclerotic bony metastasis with a novel metronomic chemobiological approach. J Pediatr Hematol Oncol. 2012; 34(5):e195-8. DOI: 10.1097/MPH.0b013e3182373e6a. View

10.

Patil V, Karpe A, Noronha V, Joshi A, Muddu V, Bhattacharjee A . Efficacy of second-line erlotinib in patients postprogression of first-line chemotherapy in head and neck cancers. Indian J Cancer. 2016; 52(4):629-31. DOI: 10.4103/0019-509X.178374. View

11.

Majumder D, Mukherjee A . Mathematical modelling of toxicity-related trade-offs in metronomic chemotherapy. IET Syst Biol. 2007; 1(5):298-305. DOI: 10.1049/iet-syb:20060085. View

12.

Noronha V, Krishna M, Patil V, Joshi A, Banavali S, Prabhash K . Metronomic therapy: chemotherapy revisited. Indian J Cancer. 2013; 50(2):142-8. DOI: 10.4103/0019-509X.117027. View

13.

Bouche G, Andre N, Banavali S, Berthold F, Berruti A, Bocci G . Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan. Ecancermedicalscience. 2014; 8:463. PMC: 4162678. DOI: 10.3332/ecancer.2014.463. View

14.

Browder T, Butterfield C, Kraling B, Shi B, Marshall B, OReilly M . Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000; 60(7):1878-86. View

15.

Kerbel R, Kamen B . The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004; 4(6):423-36. DOI: 10.1038/nrc1369. View

16.

Tandon N, Banavali S, Menon H, Gujral S, Kadam P, Bakshi A . Is there a role for metronomic induction (and maintenance) therapy in elderly patients with acute myeloid leukemia? A literature review. Indian J Cancer. 2013; 50(2):154-8. DOI: 10.4103/0019-509X.117033. View

17.

Agrawal A, Purandare N, Shah S, Puranik A, Banavali S, Rangarajan V . Response assessment in metronomic chemotherapy: RECIST or PERCIST?. Indian J Nucl Med. 2014; 29(2):74-80. PMC: 3996775. DOI: 10.4103/0972-3919.130285. View

18.

Noronha V, Tsomo U, Jamshed A, Hai M, Wattegama S, Baral R . A fresh look at oncology facts on south central Asia and SAARC countries. South Asian J Cancer. 2014; 1(1):1-4. PMC: 3876600. DOI: 10.4103/2278-330X.96489. View